FDA Approves Eladocagene Exuparvovec-Tneq for Treatment of AADC Deficiency
Eladocagene exuparvovec-tneq is the first FDA-approved gene therapy for individuals with aromatic L-amino acid decarboxylase deficiency.
Eladocagene exuparvovec-tneq is the first FDA-approved gene therapy for individuals with aromatic L-amino acid decarboxylase deficiency.
RSV vaccination is approximately 77% to 81% effective against hospital and emergency department encounters among older adults.
A gallery of portraits of prominent alumnae of color at Harvard Medical School provides inspiration for diverse current students and makes past sexist practices visible…
In the analysis, 34.7% of commercially insured patients with chronic obstructive pulmonary disease or asthma received an influenza vaccination.
When it comes to satisfying your sweet tooth, some sweeteners are better than others. What makes sugar a risk for your health, and what are…
STK19 functions in transcription-coupled DNA repair, aiding the clearance of RNAPII and advancing the repair process by positioning the ATPase subunits of TFIIH onto DNA.
Click on the article title to read more.
The sessions will include late-breaking science, clinical practice guidelines, early innovators spotlight sessions, and more.
Objective Parents and caregivers of children with neurological conditions express interest in new and developing treatments and trials; however, they have limited knowledge of, and…
This cohort study examines whether the season and postmenstrual age of preterm infants discharged from neonatal units are associated with unplanned readmission to pediatric intensive…
PURPOSE The impact of digital health on medically underserved patients is unclear. This study aimed to determine the early impact of a digital innovation to…